Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 6CNS 6Thoracic 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Melanoma 4Uveal Melanoma 2Rectal Neoplasms 2Colonic Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms, Male 2Breast Neoplasms 2Brain Neoplasms 2Pancreatic Neoplasms 1Ovarian Neoplasms 1Oligodendroglioma 1Neoplasm Metastasis 1Gliosarcoma 1Glioma 1Glioblastoma 1Ependymoma 1Astrocytoma 1

Interventions

cediranib 1carboxyamido-triazole 1Vinblastine 1Thalidomide 1Paclitaxel 1Introns 1Immunologic Techniques 1Fentanyl 1Docetaxel 1Dacarbazine 1Cisplatin 1Antimony Sodium Gluconate 190Y-octreotide, DOTA-Tyr(3)- 14-boronophenylalanine-fructose 12,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Gliosarcoma × cediranib × Dermatologic × Clear all
NCT01131234 2014-12-23

Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors

National Cancer Institute (NCI)

Phase 1 Completed
20 enrolled
BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicSarcomaThoracic

Astrocytoma, Brain Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Colonic Neoplasms, Ependymoma, Glioblastoma, Glioma, Melanoma, Oligodendroglioma, Ovarian Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Gliosarcoma, Breast Neoplasms, Male

Data powered by HemOnc (CC BY 4.0) Colophon âš¡